Collegium Pharmaceutical’s Executive Sales Signal Strategic Rebalancing Amid Market Slump
Collegium insider sales reveal a cautious, strategic 10b‑5‑1 plan amid recent price drops – investors should watch for future selling trends and upcoming pipeline milestones.
- Collegium Pharmaceutical Inc
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read